Prosecution Insights
Prosecution Insights
11 pending office actions • 10 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready • 16 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 11 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 11 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 5 (45%) |
| §102 only | 2 (18%) |
| §112 only | 1 (9%) |
| No statute on record | 3 (27%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SINGH, ANOOP KUMAR | 1 | 42.8% | +67.6% |
| BOWLES, DAVID PAUL | 1 | 75.0% | +17.5% |
| CHOWDHURY, IQBAL HOSSAIN | 1 | 73.6% | +57.8% |
| CONNORS, ALEXANDRA F | 1 | 23.5% | +44.0% |
| HOEKSTRA, JEFFREY GERBEN | 1 | 55.6% | +40.1% |
| ZHU, JIANJIAN | 1 | 59.7% | +82.5% |
| STAVROU, CONSTANTINA E | 1 | 44.2% | +31.4% |
| IVICH, FERNANDO NMN | 1 | 42.9% | +77.9% |
| FAUST, AMBER KATHLEEN | 1 | 62.3% | +50.3% |
| MISHRA, DEEPA | 1 | 31.1% | +33.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17830871 | Recombinant Adeno-Associated Virus Products and Methods for Treating Limb Girdle Muscular Dystrophy 2A | CONNORS, ALEXANDRA F | 22d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17604188 | GENE THERAPY FOR TREATING OR PREVENTING VISUAL EFFECTS IN BATTEN DISEASE | STAVROU, CONSTANTINA E | 113d overdue |
| 17265505 | PRENATAL PROBIOTIC FORMULATIONS | MISHRA, DEEPA | 96d overdue |
| 17786721 | OPTIMIZED GENE THERAPY FOR TARGETING MUSCLE IN MUSCLE DISEASES | CHOWDHURY, IQBAL HOSSAIN | 36d overdue |
| 17830871 | Recombinant Adeno-Associated Virus Products and Methods for Treating Limb Girdle Muscular Dystrophy 2A | CONNORS, ALEXANDRA F | 22d overdue |
| 19298798 | ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF MICRO-DYSTROPHIN TO TREAT MUSCULAR DYSTROPHY | SINGH, ANOOP KUMAR | 7d |
| 17431276 | USE OF A STIMULATING AGENT TO ASSAY IMMUNE CELL POTENCY | FAUST, AMBER KATHLEEN | 7d |
| 17511187 | CHIMERIC ANTIGEN RECEPTOR (CAR) NK CELLS AND USES THEREOF | ZHU, JIANJIAN | 23d |
| 17920231 | EPHA4 TARGETING COMPOUNDS AND METHODS OF USE THEREOF | BOWLES, DAVID PAUL | 28d |
| Art Unit | Apps |
|---|---|
| 1632 | 2 |
| 1654 | 1 |
| 1656 | 1 |
| 1634 | 1 |
| 3791 | 1 |
| 1631 | 1 |
| 1678 | 1 |
| 1643 | 1 |
| 1657 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19298798 | ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF MICRO-DYSTROPHIN TO TREAT MUSCULAR DYSTROPHY | SINGH, ANOOP KUMAR | 1632 | Other | Non-Final OA | 7d | Pending | Aug 13, 2025 |
| 17920231 | EPHA4 TARGETING COMPOUNDS AND METHODS OF USE THEREOF | BOWLES, DAVID PAUL | 1654 | §112 | Non-Final OA | 28d | Pending | Oct 20, 2022 |
| 17786721 | OPTIMIZED GENE THERAPY FOR TARGETING MUSCLE IN MUSCLE DISEASES | CHOWDHURY, IQBAL HOSSAIN | 1656 | §103 | Non-Final OA | 36d overdue | Pending | Jun 17, 2022 |
| 17830871 | Recombinant Adeno-Associated Virus Products and Methods for Treating Limb Girdle Muscular Dystrophy 2A | CONNORS, ALEXANDRA F | 1634 | §103 | Final Rejection | 22d overdue | Pending | Jun 02, 2022 |
| 17650273 | SMART MUSCLE TESTING DEVICES AND METHODS FOR USE THEREOF | HOEKSTRA, JEFFREY GERBEN | 3791 | §102 | Final Rejection | 34d | Pending | Feb 08, 2022 |
| 17511187 | CHIMERIC ANTIGEN RECEPTOR (CAR) NK CELLS AND USES THEREOF | ZHU, JIANJIAN | 1631 | §103 | Non-Final OA | 23d | Pending | Oct 26, 2021 |
| 17604188 | GENE THERAPY FOR TREATING OR PREVENTING VISUAL EFFECTS IN BATTEN DISEASE | STAVROU, CONSTANTINA E | 1632 | §103 | Non-Final OA | 113d overdue | Pending | Oct 15, 2021 |
| 17439092 | COMPOSITIONS AND METHODS FOR DIAGNOSING ACUTE INFECTIOUS PERITONITIS | IVICH, FERNANDO NMN | 1678 | Other | Final Rejection | 33d | Pending | Sep 14, 2021 |
| 17431276 | USE OF A STIMULATING AGENT TO ASSAY IMMUNE CELL POTENCY | FAUST, AMBER KATHLEEN | 1643 | §102 | Final Rejection | 7d | Pending | Aug 16, 2021 |
| 17265505 | PRENATAL PROBIOTIC FORMULATIONS | MISHRA, DEEPA | 1657 | Other | Non-Final OA | 96d overdue | Pending | Feb 02, 2021 |
| 17256640 | COMPOSITIONS AND METHODS FOR MEDIATING EPS | SIMMONS, CHRIS E | 1622 | §103 | Final Rejection | 75d | Pending | Dec 28, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial